Company: ANGLE plc
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Head of Regulatory Affairs See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Study Manager See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Scientist Imaging See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Technical Support Scientist See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Laboratory Scientist I (VA154) See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Study Manager See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Scientist Imaging See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Scientist Molecular See details
About ANGLE: ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA [...]Read More... from Clinical Scientist Imaging See details
ANGLE is a world-leading liquid biopsy company commercialising a patent protected platform technology that can capture rare circulating tumour cells (CTCs) from blood, in a minimally invasive way, for downstream analysis. ANGLE’s Parsortix system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical [...]Read More... from Clinical Data Analyst Molecular See details
